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Abstract: Oxidative stress is prominent in many neurodegenerative diseases. Along with mitochondrial
dysfunction and pathological protein aggregation, increased levels of reactive oxygen and nitrogen
species, together with impaired antioxidant defense mechanisms, are frequently observed in
Alzheimer’s, Parkinson’s, Huntington’s disease and amyotrophic lateral sclerosis. The presence
of oxidative stress markers in patients’ plasma and cerebrospinal fluid may aid early disease
diagnoses, as well as provide clues regarding the efficacy of experimental disease-modifying therapies
in clinical trials. In preclinical animal models, the detection and localization of oxidatively damaged
lipids, proteins and nucleic acids helps to identify most vulnerable neuronal populations and
brain areas, and elucidate the molecular pathways and the timeline of pathology progression.
Here, we describe the protocol for the detection of oxidative stress markers using immunohistochemistry
on formaldehyde-fixed, paraffin-embedded tissue sections, applicable to the analysis of postmortem
samples and tissues from animal models. In addition, we provide a simple method for the detection of
malondialdehyde in tissue lysates and body fluids, which is useful for screening and the identification
of tissues and structures in the nervous system which are most affected by oxidative stress.
Keywords: neuroketals; nitrotyrosine; 8-hydroxy-2′-deoxyguanosine; malondialdehyde;
immunohistochemistry; neurodereneration; oxidative stress; lipid peroxidation; reactive oxygen
species (ROS)
1. Introduction
Oxidative stress is defined as an imbalance between the formation and destruction of free radicals [1].
The main source of free radicals in the body is oxygen activation occurring as a result of normal or
pathological metabolic processes in cells. This leads to the formation of highly reactive superoxide
anions (O2′-), hydrogen peroxide (H2O2) and singlet oxygen 1O2, called reactive oxygen species (ROS),
which can interact with cellular molecules and damage them [2]. Lipid peroxidation is one of the major
processes occurring in oxidative stress. During lipid peroxidation, ROS attack polyunsaturated fatty acids
and induce intramolecular rearrangements of structure, with the formation of conjugated diene. In the
next step, diene reacts with oxygen molecules, resulting in the generation of lipid radicals. The radicals
further disintegrate with the formation of highly reactive 4-hydroxy-2-noneal (HNE), malondialdehyde
(MDA) and acrolein (Figure 1A). These products can, in turn, react with, e.g., cellular proteins forming
Shiff bases and Michael-adducts, thus damaging cellular macromolecules [1]. In the brain and retina,
free radicals induce peroxidation of docosahexenoic acid (DHA), which is especially enriched in the
synaptic membranes. DHA is oxidized to isoprostane-like compounds (Figure 1B), which undergo
rearrangement to form D- and E-ring neuroprostanes, also called neuroketals, due to their specific
enrichment in the nervous system (Figure 1B) [3,4]. Isoprostanes are prostaglandin-like compounds
which are unique markers of oxidative stress, because they are formed only nonenzymatically in vivo
in the process of free radical-initiated peroxidation [5].
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Figure 1. Example chemical reactions leading to formation of (A) lipid peroxidation products, (B) 
neuroketals, (C) nitrosylated tyrosine, and (D) 8-hydroxy-2′-deoxyguanosine (8-OHdG) in 
equilibrium with its tautomer 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG). 
In addition to lipids, ROS can also cause oxidative damage to proteins and nucleic acids, 
affecting essential cellular functions and activating cell death pathways [6]. For example, 
peroxynitrite (ONOO−), formed by the reaction of superoxide anion with NO, can oxidize 
lipoproteins and also trigger lipid peroxidation (via production of hydroxyl radical) with the 
formation of highly reactive products such as MDA [7]. In proteins, NO can nitrate tyrosine residues 
(Figure 1C) [8,9]. The resulting 3-nitrotyrosine can be relatively easily identified using immunological 
methods or chromatography [10], and therefore serves as a convenient oxidative stress biomarker. 
ROS can also attack and oxidize mitochondrial and nuclear DNA and RNA, with the guanine base 
being one of the most susceptible to oxidation [11,12]. Reaction with hydroxyl radicals leads initially 
to the generation of radical adduct. Then, 8-hydroxy-2′-deoxyguanosine (8-OHdG) is formed by one 
electron abstraction (Figure 1D); 8-OHdG exists in equilibrium with its tautomer  
8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG), and in the literature, both names are used 
interchangeably [12,13]. Similarly to 3-nitrotyrosine, 8-OHdG is detected using immunological, 
chromatography or mass-spectrometric assays. 
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In addition to lipids, ROS can also cause oxidative damage to proteins and nucleic acids,
affecting essential cellular functions and activating cell death pathways [6]. For example, peroxynitrite
(ONOO−), formed by the reaction of superoxide anion with NO, can oxidize lipoproteins and also
trigger lipid peroxidation (via production of hydroxyl radical) with the formation of highly reactive
products such as MDA [7]. In proteins, NO can nitrate tyrosine residues (Figure 1C) [8,9]. The resulting
3-nitrotyrosine can be relatively easily identified using immunological methods or chromatography [10],
and therefore serves as a convenient oxidative stress biomarker. ROS can also attack and oxidize
mitochondrial and nuclear DNA and RNA, with the guanine base being one of the most susceptible to
oxidation [11,12]. Reaction with hydroxyl radicals leads initially to the generation of radical adduct.
Then, 8-hydroxy-2′-deoxyguanosine (8-OHdG) is formed by one electron abstraction (Figure 1D);
8-OHdG exists in equilibrium with its tautomer 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG),
and in the literature, both names are used interchangeably [12,13]. Similarly to 3-nitrotyrosine, 8-OHdG
is detected using immunological, chromatography or mass-spectrometric assays.
Due to high metabolic demands coupled with the active consumption of oxygen, a low level
of antioxidant defense system components and saturation with polyunsaturated fatty acids, brain is
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especially vulnerable to lipid peroxidation and subsequent pathological processes [1,14–16]. Indeed,
evidence of lipid peroxidation has been reported in many neurodegenerative disorders such as
Parkinson’s disease (PD), Huntington’s Disease (HD), Alzheimer’s disease (AD) and amyotrophic
lateral sclerosis (ALS).
1.1. Parkinson’s Disease
PD is diagnosed based on the appearance of motor symptoms such as resting tremor, slowness of
movement, rigidity and dyskinesias, which are caused by the degeneration of nigrostriatal dopamine
neurons [17]. It is the second most common neurodegenerative disorder with a prevalence of 0.4% in
general population, and occurs more often in males and elderly people [18]. The exact reasons for
particular vulnerability of the nigrostriatal dopamine system to degeneration are yet to be established,
but such vulnerability may be attributed to the generation of free radicals in the process of the
enzymatic or nonenzymatic degradation of dopamine associated with the production of ROS [19].
In pathophysiological analyses of postmortem samples, protein aggregates called Lewy bodies may
be detected in the brain of the majority of PD patients [3,20,21]. Lewy bodies contain aggregated
α-synuclein as a main component, as well as a number of other proteins and lipid membrane fragments.
Aggregation of misfolded α-synuclein can impair axonal transport and proteostasis, leading to
degeneration of neurites and cell death [22,23].
In the context of oxidative stress, elevated concentrations of MDA and NME have been reported
in the plasma and cerebrospinal fluid (CSF) of PD patients [24]. Lipid peroxidation products such
as acrolein have been shown to modify α-synuclein, resulting in disturbances in mitochondrial
function [1,14]. Moreover, the HME and MDA adducts are detectable in Lewy bodies, implying the
involvement of a lipid peroxidation process in PD pathogenesis [14].
1.2. Huntington’s Disease
HD is a hereditary disorder with a prevalence between of 2.17 to 7.33 cases per 100,000 people,
depending on the geographic region [25]. In HD, an expansion (>36) of trinucleotide (CAG) sequence
repeats leads to an abnormally long polyglutamine stretch in mutant huntingtin protein, and to the
production of aggregation-prone homopolymeric proteins. Increasing length of the expanded CAG
repeat sequence correlates with earlier disease onset [26–28]. Major symptoms of HD include severe
motor and psychiatric disturbances caused by the degeneration of striatal GABAergic medium spiny
neurons and the cortical neurons projecting to them. Progressive degeneration of these neurons results
in the gradual worsening of symptoms and, eventually, death at about 15–20 years after disease onset.
Aggregation of mutant huntingtin and homopolymeric proteins leads to the appearance of nuclear
and cytoplasmic inclusions in affected neuronal populations, causing proteostasis dysregulation,
neurotransmission defects, mitochondrial dysfunction and oxidative stress [27–31]. Decreased capacity
of antioxidant defense systems and increased oxidative stress contribute to neurodegeneration [29]
and, indeed, the levels of oxidative stress markers, such as lipid peroxidation products and lactate in
plasma, increase with the disease progression from the asymptomatic to symptomatic HD phase [32].
HD patients exhibit increased levels of 8-OHdG and nitrotyrosine in the brain, as well as in serum and
leukocytes [33–35]. Importantly, 8-OHdG levels in leukocytes may serve a very sensitive biomarker of
HD progression [29,36].
1.3. Alzheimer’s Disease
AD is currently an incurable neurodegenerative disorder manifesting as age-related progressive
cognitive decline in affected patients [37]. AD is considered to be the cause of 50–75% of all dementia
cases, and is estimated to affect more than 30 million people worldwide [38–40].
The exact causes of AD are not clear, though mutations in the PSEN1, PSEN2 and APP genes
and APOE gene variants can contribute to its development. AD is characterized by progressive
synaptic loss and neurodegeneration affecting multiple brain regions [41–44]. The main hallmarks
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of pathology observed in AD brains are extracellular accumulation of amyloid-β (Aβ) peptides and
hyperphosphorylation of the microtubule-associated protein Tau, leading to the accumulation of
amyloid plaques and neurofibrillary tangles [42,45].
Oxidative stress has long been implicated in AD pathology. Complex interplay between
proteostasis inhibition caused by abnormal protein aggregation, mitochondrial dysfunction, altered
calcium dynamics, increased ROS production as well as depletion of cellular antioxidant defense
mechanisms creates a vicious cycle of pathology progression leading to synaptic dysfunction, synaptic
loss and eventual neurodegeneration [46–49]. On a molecular level, lipid peroxidation, nuclear and
mitochondrial DNA damage and increased protein oxidation markers have been detected in the brain,
CSF or plasma of AD patients at different stages of the disease [50–58].
1.4. Amyotrophic Lateral Sclerosis
ALS is a rare neurodegenerative disorder caused by the degeneration of motor neurons in the
brain and spinal cord with a prevalence 4.1–8.4 per 100,000 people. The typical onset of the symptoms
occurs at 51–66 years and the majority of patients die within 2–5 years after diagnosis [59,60]. The exact
reason of motor neuron death in ALS is yet to be determined. The vast majority of ALS cases are
sporadic, but approximately 10% are inheritable. Among familial ALS patients, about 20% carry
mutations in superoxide dismutase (SOD) gene coding an enzyme of antioxidant defense destroying
superoxide radicals in the body [61,62]. Mutant SOD can produce ROS via aberrant reaction, as shown
in in vitro assays. Consistent with the ROS-producing capacity of mutated SOD, increased levels
of protein adducts with HNE were found in animal ALS models. In particular, HNE modified
dihydropyrimidinase-related protein 2 (DRP-2), heat shock protein 70 and α-enolase were reported to
be present in the tissues of animals with ALS-like symptoms [1,14]. Thus, it is clear that ROS and lipid
peroxidation may play a role in the pathogenesis of ALS.
1.5. Is Oxidative Stress the Cause or a Consequence of Pathological Changes in Brain Cells?
It is still unclear whether oxidative stress is the cause or a consequence of other pathological
cellular changes, such as pathological protein aggregation, neurotransmitter oxidation, mitochondrial
dysfunction, inflammation or deregulation of antioxidant pathways [29,46,63–66]. Nevertheless,
reducing cellular ROS levels may be considered a promising neuroprotective or neurorestorative
therapy, not only for the four neurodegenerative diseases mentioned above, but also for other conditions
damaging the brain, for example, traumatic brain injury [67]. However, the application of antioxidant
drugs for the treatment of neurodegenerative diseases has mostly been unsuccessful, probably,
due to incorrect and/or insufficient therapy timing and their low penetrance through the blood-brain
barrier [6,68,69]. Thus, further studies are needed to understand the role of oxidative stress in the
pathogenesis of neurodegenerative disorders, to identify druggable targets involved in the oxidative
stress-related processes and to develop novel therapeutics for the management of neurodegeneration.
2. Experimental Design
The overall level of oxidative damage in the organism can be evaluated by monitoring
oxidative/nitrosative stress markers such as MDA in body fluids such as blood, serum, cerebrospinal
fluid and even urine. However, we are generally still lacking the methods to reliably detect and monitor
levels of oxidative damage in living tissue [70]. Nevertheless, considerable progress has been achieved
in detecting oxidative stress markers in tissue lysates and histological sections. Many products formed
in the process of lipid peroxidation can be measured using biochemical methods, but some of these
measurements are expensive, as they require complicated purification processes, modern equipment
and significant labor input. However, the evaluation of the content of MDA and other aldehydes
produced during lipid peroxidation (or the level of thiobarbituric acid-reacting substances, TBARS)
can be easily performed in a color reaction with thiobarbituric acid. Although the method has a number
of limitations, the greatest of which is the fact that the readout reflects the amount of TBARs rather than
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MDA itself, it can still be useful for rapid screening and quantitative assessment of the intensity of lipid
peroxidation processes in preclinical and clinical samples. Coupled with more sophisticated methods
of oxidative stress analysis such as immunohistochemistry with specific antibodies against oxidative
stress markers, it can provide insights into the mechanisms and pathogenesis of neurodegenerative
disorders and facilitate the process of drug discovery. Here, we describe protocols to detect MDA in
tissue lysates and oxidative stress markers in formaldehyde-fixed, paraffin-embedded brain sections.
Together, these methods provide complementary information on oxidative stress levels. While the
MDA detection in tissue samples can be suitable for clinical settings, it lacks the cellular resolution
necessary to study oxidative stress levels in specific cell types. In contrast, the detection of oxidative
stress markers in tissue sections utilizing standard imunohistochemical methods makes it possible
to distinguish oxidative stress levels in individual cells and, by costaining with specific markers,
in selected neuronal populations. For immunohistochemical detection, suitable tissue samples have to
be obtained either by biopsy or postmortem, which is a clear drawback of the method. However, it is
extremely useful for preclinical studies in animal models.
As an example of immunohistochemical detection, we describe here a protocol for detecting
nitrotyrosine, neuroketals or 8-OHdG in dopaminergic neurons, visualized by costaining with antibody
detecting tyrosine hydroxylase (TH), an established marker for this neuronal population.
Materials
To prepare the buffers, either dd (double distilled) or milliQ H2O can be used.
• 10× Citra-buffer (BioGenex #HK086-9K)
• 30% H2O2 (J.T.Baker #7047 or Merck #1.07209.1000)
• Normal swine serum (Dako #X0901)
• Antinitrotyrosine antibody (Alpha Diagnostic #NITT12-A) dilute 1:200
• Antineuroketals antibody (Chemicon #AB5611) dilute 1:2000
• Anti-8OHdG antibody (Chemicon #AB5830) dilute 1:1000
• Anti-TH antibody (Chemicon #AB1542) dilute 1:2000
• Biotinylated goat antirabbit IgG antibody (H+L) (Vector Laboratories #BA-1000) dilute 1:400
• Biotinylated horse antigoat IgG antibody (H+L) (Vector Laboratories #BA-9500) dilute 1:400
• Biotinylated rabbit antisheep IgG antibody (H+L) (Vector Laboratories #BA-9600) dilute 1:400
• Avidin-biotin-HRP (ABC) kit (Vector Laboratories # PK-4000)
• 3, 3′-diaminobenzidine (DAB) (Sigma #D4293-50SET)
• HistoGreen kit (Linaris #E109)
3. Procedure
3.1. Immunohistochemical Detection of Oxidative Stress Markers in Dopaminergic Neurons
Below, we describe the detailed protocol for immunohistochemical detection of nitrotyrosine,
neuroketals and 8-OHdG in a selected neuronal population, using dopaminergic neurons as an example.
Dopaminergic neurons are readily visualized with antityrosine hydroxylase (TH) immunostaining.
Other markers (such as dopamine transporter (DAT), acetylcholine esterase (AChE), neuronal nuclei
(NeuN), β-III-tubulin etc.) can be used to study different populations of neural cells [71].
3.1.1. Deparaffination and Rehydration. Time for Completion: Approx.60 min
During this step, traces of paraffin are removed and the sections are rehydrated. It is practical to
place the slides in a slide rack and move the rack between containers with corresponding solutions
(i.e., three containers with xylene, six with different ethanol concentrations, and one with PBS).
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1. Place the slides in a slide rack and incubate for 10 min in xylene
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2. Repeat twice with fresh changes of xylene.
3. Incubate twice for 5 min in absolute ethanol.
4. Incubate twice for 5 min in 95% ethanol (v/v solution in H2O).
5. Incubate twice for 5 min in 70% ethanol.
6. Incubate 10 min in PBS.
3.1.2. Antigen Retrieval and Peroxidase Blocking. Time for Completion: 1 h 30 min
Heat-induced antigen retrieval improves the binding of the antibody by improving the accessibility
of the target epitopes, which can be masked during the fixation and paraffin embedding process. For the
detection of antigen-bound antibodies, horseradish peroxidase (HRP) enzyme is utilized; its localization
on the sections is detected by the presence of an insoluble colored product of HRP-catalyzed conversion
of chromogenic substrate (DAB or HistoGreen). If not blocked, the endogenous peroxidase will
also convert the chromogenic substrate, resulting in unspecific background staining. Incubation
with saturating amounts of H2O2 efficiently and irreversibly inactivates the endogenous peroxidase.
While most protocols suggest blocking peroxidase in 3% H2O2 solution [72], such a high concentration
of peroxide may affect the epitopes on some antigens recognized by antibodies. We have empirically
found that for the antibodies used in this protocol, blocking in 1.5% H2O2 solution produces optimal
results with reasonably low background.
1. Place the slides in heat-resistant container with sufficient 1× Citra-buffer to completely cover
them and heat in a microwave oven for 3 min at 800 Watt.
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CRITIC L STEP The PAP pen will create a ydrophobic barrier o that the antibody solution
will stay on the section. It is critically important that the hydrophobic solution does not come
into contact with the section, as it will essentially prevent any aqueous solution from reaching
the section.
2. Place each slide horizontally in a oist chamber and cover each brain section with approximately
100 µL of blocking solution.
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ITI L S EP It is critically important for the blocking solution at this step, and for the
antibody solution in the following steps, to cover the ntire section; therefore, the volume should
be adjusted depending on the section size. Incubation in a m ist chamb r— .g., a box line
with w t filter paper—pr vents th evaporation of the solution, making it possible to reduce the
solution volume.
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3. Incubate 30–60 min at room temperature.
4. Carefully remove the blocking solution. Do not rinse the slides.
5. Cover each brain section with approximately 100 µL of one of the primary antibodies diluted in
blocking solution: antinitrotyrosine diluted 1:200, antineuroketals diluted 1:2000 or anti-8-OHdG
diluted 1:1000.
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ITI L STEP Optimal antibody dilution should be empirically tested for each antibody
and, ideally, for each new batch, in a pilot experiment. Dilutions may range from 1:50 up to 1:5000
and even higher, depending on the antibody and antigen.
6. Incubate overnight (approximately 15 h) at 4 ◦C in a moist chamber.
7. On the next day, move the slides to a slide rack and wash three times for 10 min in PBS.
8. Remove liquid from slides, place them horizontally and cover each brain section with
approximately 100 µL of the proper secondary biotinylated antibody diluted 1:400 in PBS.
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CRITICAL STE The secondary antib dy dep nds on the nimal pecies in which the primary
antibody was raised. For example, antinitrotyrosine antibodies (raised in rabbit) use antirabbit
secondary antibodies, while antineuro etals or anti-8-OHdG antibodies (both raised in goat)
use antigoat secondary antibodies.
9. Incubate for 30 min at room temperature; meanwhile prepare the avidin-biotin-HRP (ABC) mixture.
10. Move the slides to a slide rack and wash three times for 10 min in PBS.
11. Remove the liquid from the slides, place them horizontally and cover each brain section with
approximately 100 µL ABC mixture.
12. Incubate at r om temperature for 30 min.
13. M ve the sl des to a slide rack and wash three times for 10 min in PBS.
14. Remove th liquid from the slides, place them horizontally and cover each brain section with
approximately 100 µL of DAB solution.
15. I cubate at room temperature for 30 sec–10 min (depending o the antibody) until a br wn
color develops.
Meth ds Pr toc. 2020, 3, x FOR PEER REVIEW 6 of 14 
 
3.1.1. Deparaffination and Rehydration. Time for Completion: Approx.60 min 
During this step, traces of paraffin are removed and the sections are rehydrated. It is practical to 
place the slides in a slid  rack and m ve the rack between containers with corresponding solutions 
(i.e., three containers with xylene, six with different ethanol concentrations, and one with PBS). 
 CRITICAL STEP It is important to not let t e slides dry at any stage of the protocol. 
1. Place the slides in a slide rack and incubate for 10 min in xylene 
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blocking in 1.5% H2O2 soluti  produces ptimal results with reasonably low background. 
1. Place the slides in heat-resistant container with sufficient 1× Citra-buffer to completely cover 
them and heat in a microwave oven for 3 min at 800 Watt. 
 I I  STEP Check that the solution is boiling. 
Alternatively, antigen retrieval can be performed in 0.1 M citrate buffer, pH 6.0: 40 mM sodium 
citrate dihydrate, 60 mM citric acid. 
2. Continue eating for an additional 8 min at 360 Watt. 
3. Let the container with the slides cool at room temperature for 20–30 min. 
4. Wash the slides three times for 5 min in PBS. 
5. Block endogenous peroxidase by incubating the slides 30 min in 1.5% H2O2 solution. 
6. Wash the slides three times for 5 min in PBS. 
3.1.3. Immunolabelling with the First Antibody. Time for Completion: 16–17 h 
Before the sections are incubated with primary antibodies, the unspecific binding of proteins to 
tissue is blocked by incubation with 5% normal swine serum. 
1. Remove liquid from the slides and carefully encircle the sections with a PAP pen (Merck 
#Z672548 or similar). 
 CRITICAL STEP The PAP pen will create a hydrophobic barrier so that the antibody 
solution will stay on the section. It is critically important that the hydrophobic solution does not 
come into contact with the section, as it will essentially prevent any aqueous solution from 
reaching the section. 
2. Place each slide horizontally in a moist chamber and cover each brain section with 
approximately 100 µL of blocking solution. 
 CRITICAL STEP It is critically important for the blocking solution at this step, and for the 
antibody solution in the following steps, to cover the entire section; therefore, the volume should 
I I The exact incub ti n time dep n s on the ntibody and quality of the
sections. For all slides in one staini g batc , the sa e incubation time sho ld be maintain d to
enable comparisons to be made of the staining between different slides. The intensity of DAB
st ining, however, is not linearly dependent on the antigen concentrati n [73].
16. St p he reaction by i mersing the slides in H2O.
17. Move th slides to a slid rack a d wash three times for 10 min i PBS.
3.1.4. Immunolabelling with the Second antibody. Time for Completion: 19–20 h
1. Block HRP from the first st ining by incubating the slides for 30 min in 1.5% H2O2 solution.
2. Wash three times for 10 min in PBS.
3. Remove the liquid from th slides, plac the horizontally and cover each brain section with
several drops of avidin solution (Vector Laboratories #SP-2001).
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approximately 100 µL of blocking solution. 
 CRITICAL STEP It is critically important for the blocking solution at this step, and for the 
antibody solution in the following steps, to cover the entire section; therefore, the volume should 
ITI L STEP Incuba on with avidi and, subs qu ntly, with biotin is necessary to block
the nonspecific bi ding of avidi -conjugat HRP to the first seco dary antibody.
4. Incubat for 15 min at r om temperature.
5. Wash for 10 min in PBS.
6. Remove the liquid from the slides, place them horizontally and cover ach brain section with
everal drops of biotin solutio (Vecto Laboratories #SP-2001).
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5. Block endogenous peroxidase by incubating the slides 30 min in 1.5% H2O2 solution. 
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tissue is blocked by incubation with 5% normal swine serum. 
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solution will stay on the section. It is critically important that the hydrophobic solution does not 
come into contact with the section, as it will essentially prevent any aqueous solution from 
reaching the section. 
2. Place each slide horizontally in a moist chamber and cover each brain section with 
approximately 100 µL of blocking solution. 
 CRITICAL STEP It is critically important for the blocking solution at this step, and for the 
antibody solution in the following steps, to cover the entire section; therefore, the volume should 
ITI L STEP Incubation with avidin and, subs quently, with biotin is necessary to block
the nonspecific bi ding of avidin-conjugated HRP to the first secondary antibody.
7. Incubate for 15 min at room temperature.
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8. Wash three times for 10 min in PBS.
9. Cover each brain section with approximately 100 µL of one of the second primary antibodies
diluted in blocking solution: antityrosine hydroxylase diluted 1:2000
10. Incubate overnight (approximately 15 h) at 4 ◦C in a moist chamber.
11. On the next day, move the slides to a slide rack and wash three times for 10 min in PBS.
12. Remove the liquid from the slides, place them horizontally and cover each brain section with
approximately 100 µL of proper secondary biotinylated antibodies diluted 1:400 in PBS.
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utilized; its localization on the sections is detected by the presence of an insoluble colored product of 
HRP-catalyzed conversion of chromogenic substrate (DAB or HistoGreen). If not blocked, the 
endogenous peroxidase will also convert the chromogenic substrate, resulting in unspecific 
background staining. Incubation with saturating amounts of H2O2 efficiently and irreversibly 
inactivates the endogenous peroxidase. While most protocols suggest blocking peroxidase in 3% 
H2O2 solution [72], such a high concentration of peroxide may affect the epitopes on some antigens 
recognized by antibodies. We have empirically found that for the antibodies used in this protocol, 
blocking in 1.5% H2O2 solution produces optimal results with reasonably low background. 
1. Place the slides in heat-resistant container with sufficient 1× Citra-buffer to completely cover 
them and heat in a microwave oven for 3 min at 800 Watt. 
 CRITICAL STEP Check that the solution is boiling. 
Alternatively, antigen retrieval can be performed in 0.1 M citrate buffer, pH 6.0: 40 mM sodium 
citrate dihydrate, 60 mM citric acid. 
2. Continue heating for an additional 8 min at 360 Watt. 
3. Let the container with the slides cool at room temperature for 20–30 min. 
4. Wash the slides three times for 5 min in PBS. 
5. Block endogenous peroxidase by incubating the slides 30 min in 1.5% H2O2 solution. 
6. Wash the slides three times for 5 min in PBS. 
3.1.3. Immunolabelling with the First Antibody. Time for Completion: 16–17 h 
Before the sections are incubated with primary antibodies, the unspecific binding of proteins to 
tissue is blocked by incubation with 5% normal swine serum. 
1. Remove liquid from the slides and carefully encircle the sections with a PAP pen (Merck 
#Z672548 or similar). 
 CRITICAL STEP The PAP pen will create a hydrophobic barrier so that the antibody 
solution will stay on the section. It is critically important that the hydrophobic solution does not 
come into contact with the section, as it will essentially prevent any aqueous solution from 
reaching the section. 
2. Place each slide horizontally in a moist chamber and cover each brain section with 
approximately 100 µL of blocking solution. 
 CRITICAL STEP It is critically important for the blocking solution at this step, and for the 
antibody solution in the following steps, to cover the entire section; therefore, the volume should 
CRITICAL STEP The choice of secondary antibody depends on the nimal species in which the
primary antibodies were raised. For example, for antityrosine hydroxylase antibodies (raised in
sheep), use antisheep secondary antibodies.
13. Incubate for 30 min at room temperature; meanwhile prepare the avidin-biotin-HRP
(ABC) mixture.
14. Move the slides to a slide rack and wash three times for 10 min in PBS.
15. Remove the liquid from the slides, place them horizontally and cover each brain section with
approximately 100 µL ABC mixture.
16. Incubate at room temperature for 30 min.
17. Move the slides to a slide rack and wash three times for 10 min in PBS.
18. Remove the liquid from the slides, place them horizontally and cover each brain section with
approximately 100 µL of HistoGreen solution.
19. Incubate at room temperature for 30 sec–10 min (depending on the antibody) until a green/blue
color develops.
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Alternatively, antigen retrieval can be performed in 0.1 M citrate buffer, pH 6.0: 40 mM sodium 
citrate dihydrate, 60 mM citric acid. 
2. Continue eating for an additional 8 min at 360 Watt. 
3. Let the container with the slides cool at room temperature for 20–30 min. 
4. Wash the slides three times for 5 min in PBS. 
5. Block endogenous peroxidase by incubating the slides 30 min in 1.5% H2O2 solution. 
6. Wash the slides three times for 5 min in PBS. 
3.1.3. Immunolabelling with the First Antibody. Time for Completion: 16–17 h 
Before the sections are incubated with primary antibodies, the unspecific binding of proteins to 
tissue is blocked by incubation with 5% normal swine serum. 
1. Remove liquid from the slides and carefully encircle the sections with a PAP pen (Merck 
#Z672548 or similar). 
 CRITICAL STEP The PAP pen will create a hydrophobic barrier so that the antibody 
solution will stay on the section. It is critically important that the hydrophobic solution does not 
come into contact with the section, as it will essentially prevent any aqueous solution from 
reaching the section. 
2. Place each slide horizontally in a moist chamber and cover each brain section with 
approximately 100 µL of blocking solution. 
 CRITICAL STEP It is critically important for the blocking solution at this step, and for the 
antibody solution in the following steps, to cover the entire section; therefore, the volume should 
I I The exact incubati n time dep n s on the antibody and quality of the
sections. For all slides in one staining batc , the sa e incubation time sho ld be maintain d to
enable comparisons to e made of the staini g betwee different slides.
20. Stop the reaction by imm rsing th slides in ddH2O
21. M ve the slide to a slide rack and wash three times for 10 min in ddH2O.
3.1.5. Dehydration and Mounting. Tim for Compl tion: Approx. 15 h
For prolonge storag (i.e., ye rs), the sections are dehydrated and cover d with cov rslips in a
hydrophobic mounti g edium.
1. Incubate twice for 3 min in 70% ethanol.
2. Incubate twice for 3 min in 95% ethanol.
3. Incubate twice for 5 min in absolute ethanol.
4. Incubate twice for 5 min in xylene.
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Before the sections are incubated with primary antibodies, the unspecific binding of proteins to 
tissue is blocked by incubation with 5% normal swine serum. 
1. Remove liquid from the slides and carefully encircle the sections with a PAP pen (Merck 
#Z672548 or similar). 
 CRITICAL STEP The PAP pen will create a hydrophobic barrier so that the antibody 
solution will stay on the section. It is critically important that the hydrophobic solution does not 
come into contact with the section, as it will essentially prevent any aqueous solution from 
reaching the section. 
2. Place each slide horizontally in a moist chamber and cover each brain section with 
approximately 100 µL of blocking solution. 
 CRITICAL STEP It is critically important for the blocking solution at this step, and for the 
antibody solution in the following steps, to cover the entire section; therefore, the volume should 
ITI L STEP Work with xyle e m st be done un er fume hood.
5. Using a glass rod, put several drops of Eukitt mounti g medium (Merck #03989 or similar)
in each sect on.
6. Cov r secti ns with coverslip to avoid the formati n of b bbles.
7. Keep overnight at room temperatu e under the fum hood to dry.
3.2. Evaluation of MDA Content in Tiss e Lysates. Time for Completion Approximately 1 h
An easy techn que to evaluate the level of lip d peroxida ion in tissue samples is the analysis
of the conce tration of colo ed/fluorescent product formed in reaction with thiobarbituric acid in
acidic conditions upon heating; this approach is widely referred to as MDA content measurement.
The method is simple and straightforward, and the basic protocol is provided below, although
numerous variations exist.
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1. Homogenize the tissue sample in 50 mM Tris-HCl (pH 7.2) (10% w/v ratio). OPTIONAL STEP
Cells can be fractionated before measurements by centrifugation if desired. Buffers and solutions
other than Tris-HCl (pH 7.2) can be used to homogenize the tissue sample. In particular, Oakes et
al. (2002) report using 1.15% KCl solution for this purpose [74]. Buffers containing tris-maleate
(≤40 mM), imidazole (≤20 mM) or 4-morpholine propanesulfonic acid ≤ 20 mM) also do not
interfere with the assay readout. However, avoid sucrose-containing buffers, as sucrose can
interact with thiobarbituric acid [75]. There is a concern regarding the continuous production
of MDA during the process of sample handling. While it is generally not a big problem for
preclinical measurements, where appropriate controls are easily available and results are usually
interpreted within one experiment, it can be an issue with clinical samples. To minimize MDA
production during sample handling, an antioxidant, e.g., butylated hydroxytoluene (35 µM),
can be added to the tissue homogenization buffer [74]. To improve the solubilization of tissue
components, sodium dodecyl sulfate can be added to the reaction mixture at concentrations of,
e.g., 12.4 mM [74,75].
2. Add trichloroacetic acid (7–10% of the final volume) and mix well. We successfully used the
following ratio: 700 µL of homogenate and 500 µL of 15% trichloroacetic acid.
3. Centrifuge at 10,000× g for 10 min to remove precipitated proteins.
4. Collect the supernatant and mix it with 0.75% thiobarbituric acid (1:1), incubate in a water bath at
100 ◦C for 15–20 min, cool on ice for 5 min and centrifuge at 1000× g for 10 min to remove any
insoluble inclusions.
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3.1.3. Immunolabelling with the First Antibody. Time for Completion: 16–17 h 
Before the sections are incubated with primary antibodies, the unspecific binding of proteins to 
tissue is blocked by incubation with 5% normal swine serum. 
1. Remove liquid from the slides and carefully encircle the sections with a PAP pen (Merck 
#Z672548 or similar). 
 CRITICAL STEP The PAP pen will create a hydrophobic barrier so that the antibody 
solution will stay on the section. It is critically important that the hydrophobic solution does not 
come into contact with the section, as it will essentially prevent any aqueous solution from 
reaching the section. 
2. Place each slide horizontally in a moist chamber and cover each brain section with 
approximately 100 µL of blocking solution. 
 CRITICAL STEP It is critically important for the blocking solution at this step, and for the 
antibody solution in the following steps, to cover the entire section; therefore, the volume should 
Thiobarbi uric acid is poorly soluble in water; its aqueous s lution is
unstable and should be prepared freshly before each test. Some manuals recommend dissolving
thiobarbituric acid directly in 20% trichloroacetic acid to a 0.5% final concentration. According
to these manuals, such a solution can be stored for about a month at room temperature
without precipitation.
5. Measure the absorbance of the resulting supernatant at 532 nm (A532), with 580 nm as the
reference wavelength (used for baseline correction) using a suitable spectrophotometer with a
cuvette with a width of 1 cm. OPTIONAL STEP It is also possible to measure the assay readout
fluorometrically using the following settings: excitation at 515 nm, emission at 553 nm [74].
6. MDA quantity is calculated as C(MDA) = (A532 − A580)/K, where K is a millimolar extinction
coefficient equal to 155 mM−1 cm−1. Blanc sample containing the sample homogenization buffer
and undergoing the same treatment as experimental samples on all steps of the analysis should
be included [76,77]. OPTIONAL STEP The reaction product can be extracted with n-butanol to
assess the quantity of the reaction product only in lipid fraction [74,75].
4. Expected Results
The reliable interpretation of the immunostaining results strongly depends on the quality of the
histological sections. Here, we describe the protocol for the immunostaining of histological sections
from formaldehyde-fixed brains embedded in paraffin. Meanwhile, in the present study, fixation in
formaldehyde, paraffin embedding and sectioning at 5µm thickness was shown to be a robust method to
obtain good quality brain sections for immunostaining. This method requires more hands-on time than
producing free-floating 30–40 µm sections on vibratome or cryostat. Also, using fluorescently labelled
secondary antibodi a d confocal microscopy makes it poss ble to more precis ly col calize antigens.
Howev r, the fluorescently labelled sections cannot be stored for prolonged periods due to the fading
that occurs of the fluorescent signal. In contrast, immun histochemically stained sections can be stored
for years without noticeable loss of sig al, and can asily be scanned in an automated slide scanner
(such as Pannoramic Digital Slide Scanners (3DHistech)) and used for unbiased computer-assisted
image qua tification [78]. Representative images of immunostained sections are shown in Figure 2;
see also [79].
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Figure 2. Representative images of mouse midbrain sections immunostained for 8-hydroxy-2′-
deoxyguanosine (8-OHdG), nitrotyrosine and neuroketals (brown) in combination with tyrosine 
hydroxylase (TH, blue) to identify dopaminergic neurons. Scale bars: main image, 100 µm; inset, 40 
µm. 
Although easy to perform, the present method for the evaluation of MDA content in tissue 
lysates has a number of limitations which should be kept in mind when interpreting the results. First 
of all, not only MDA, but also many other aldehydes produced during the lipid peroxidation process, 
and lipid-peroxidation unrelated substances, such as some proteins, sucrose, urea, plasma 
components, etc. may react with thiobarbituric acid and form a colored product, leading to 
overestimations of the MDA concentration in the sample. The presence of blood in the sample, in 
particular, hemolyzed erythrocytes, can interfere with the assay readout. To minimize interference 
from sialic acid, correcting absorbance values collected at wavelength λ532 to values collected with 
λ/580 is recommended [75]. 
To conclude, the analysis of TBARS concentration in tissue samples is a cheap and easy screening 
assay which can be performed prior to application of more advanced methods to analyze the 
products of oxidative stress in preclinical and clinical samples. The spatial resolution of the MDA 
analysis method to detect oxidative stress can be improved if it is followed by immunohistochemical 
analysis of tissues with high levels of TBARS for the presence of 8-OHdG, nitrotyrosine or 
neuroketals, as described above. The combination of these two techniques represents an affordable 
yet reliable option for analysis of oxidative stress levels in tissue samples. 
5. Reagents Setup 
• Phosphate-buffered saline (PBS) pH 7.4: 137 mM NaCl, 2.7 mM KCl, 8 mM Na2PO4 and 1.5 mM 
KH2PO4 in H2O 
• 1× Citra-buffer: dilute 1 part of 10× stock solution (BioGenex #HK086-9K, stored at 4 °C) with 9 
parts of H2O; prepare fresh before use 
• 1.5% H2O2 in PBS: dilute 12.5 mL 30% H2O2 (J.T.Baker #7047 or Merck #1.07209.1000) in 237.5 mL 
PBS 
• Blocking solution: 5% (v/v) normal swine serum (Dako #X0901) in PBS 
• Avidin-biotin-HRP (ABC) mixture (Vectоr Laboratories # PK-4000): to 1 mL PBS add 10 µL 
solution A, mix and add 10 µL solution B, mix, and let stand at room temperature for at least 20 
min before use. 
• 15% Tricholoacetic acid 
• 0.75% Thiobarbituric acid (make fresh before each use): mix 0.75 g of thiobarbituric acid powder 
with 100 mL ddH2O and warm the solution until dissolved. 
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Although easy to perform, the present method for the evaluation of MDA content in tissue lysates
has a number of limitations which should be kept in mind wh n interpreting the results. First of all,
not only MDA, but also any other alde ydes produced during the lipid peroxidation proces ,
and lipid-peroxidation nrelated substances, such as some proteins, sucrose, urea, plasma c m onents,
etc. may react with thiobarbituric acid and form a colored pr duct, leadi g to overestimations of the
MDA concentration in th sample. The presence of blood in the sample, in particular, h molyzed
erythrocytes, can interfere with the assay readout. To minimize interference from sialic acid, correcting
absorbance values collected at wavelength λ532 to values collected with λ/580 is reco m nded [75].
To conclu e, the analysis of TBARS conc ntration in tissue samples is a cheap and easy screening
assay which can be performed prior to application of more advanced methods to analyze the products
of oxidative stress in preclinical and clinical samples. The spatial resolution of the MDA analysis
method to detect oxidative stress can be improved if it is followed by immunohistochemical analysis of
tissues with high levels of TBARS for the presence of 8-OHdG, nitrotyrosine or neur ketals, as described
bove. The combination of these two techniques represents an affordable y t reliable option for analysis
of oxidative stress levels in tissue samples.
5. Reagents Setup
• Phosphate-buffered saline (PBS) pH 7.4: 137 mM NaCl, 2.7 mM KCl, 8 mM Na2PO4 and 1.5 mM
KH2PO4 in H2O
• 1× Citra-buffer: dilute 1 part of 10× stock solution (BioGenex #HK086-9K, stored at 4 ◦C) with 9
parts of H2O; prepare fresh before use
.5% H2O2 in PBS: dilute 12.5 mL 3 % H2O2 (J.T.Baker #7047 or Merck #1.07209.1000) in 237.5 mL PBS
• Blocking solution: 5% (v/v) normal swine serum (Dako #X0901) in PBS
Avidin-bioti -HRP (ABC) mixture (Vector Laboratori s PK-4000): to 1 mL PBS add 10 µL solution
A, mix and add 10 µL solution B, mix, and let stand at room temperature for at least 20 min
before use.
15% Trich loacetic acid
• 0.75% Thiobarbituric acid (make fresh before each use): mix 0.75 g of thiobarbituric acid powder
with 100 mL ddH2O and warm the solution until dissolved.
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• 50 mM Tris HCl buffer with pH 7.2–7.4 (1 L): Disslove 6.2 g Tris in 900 mL ddH2O, adjust pH with
HCl solution and afterwards, adjust volume to 1 L.
Author Contributions: Conceptualization, Y.S. and A.D.; methodology, Y.S. and A.D.; data collection and analysis,
Y.S. and A.D.; images for Figure 2, A.D.; writing—original draft preparation, review and editing, Y.S. and A.D.;
funding acquisition, Y.S. and A.D. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by the Academy of Finland grants #1325555, 293392, #319195 and Päivikki
and Sakari Sohlberg Foundation. Open access funding provided by University of Helsinki.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Taso, O.V.; Philippou, A.; Moustogiannis, A.; Zevolis, E.; Koutsilieris, M. Lipid peroxidation products and
their role in neurodegenerative diseases. Ann. Res. Hosp. 2019, 3, 1–10. [CrossRef]
2. Borza, C.; Muntean, D.; Dehelean, C.; Săvoiu, G.; S¸erban, C.; Simu, G.; Andoni, M.; Butur, M.; Drăgan, S.
Oxidative stress and lipid peroxidation—A lipid metabolism dysfunction. In Lipid Metabolism; Baez R.V.
InTech: Rijeka, Croatia, 2013; pp. 23–38.
3. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy
bodies. Nature 1997, 388, 839–840. [CrossRef] [PubMed]
4. Shahmoradian, S.H.; Lewis, A.J.; Genoud, C.; Hench, J.; Moors, T.E.; Navarro, P.P.; Castaño-Díez, D.;
Schweighauser, G.; Graff-Meyer, A.; Goldie, K.N.; et al. Lewy pathology in Parkinson’s disease consists of
crowded organelles and lipid membranes. Nat. Neurosci. 2019, 22, 1099–1109. [CrossRef] [PubMed]
5. Milne, G.L.; Yin, H.; Hardy, K.D.; Davies, S.S.; Roberts, L.J. Isoprostane generation and function. Chem. Rev.
2011, 111, 5973–5996. [CrossRef]
6. Liu, Z.; Zhou, T.; Ziegler, A.C.; Dimitrion, P.; Zuo, L. Oxidative stress in neurodegenerative diseases:
From molecular mechanisms to clinical applications. Oxidative Med. Cell. Longev. 2017, 2017, 2525967.
[CrossRef] [PubMed]
7. Carbonell, T.; Rama, R. Iron, oxidative stress and early neurological deterioration in ischemic stroke.
CMC 2007, 14, 857–874. [CrossRef]
8. Ischiropoulos, H. Biological tyrosine nitration: A pathophysiological function of nitric oxide and reactive
oxygen species. Arch. Biochem. Biophys. 1998, 356, 1–11. [CrossRef]
9. Ischiropoulos, H.; Zhu, L.; Chen, J.; Tsai, M.; Martin, J.C.; Smith, C.D.; Beckman, J.S. Peroxynitrite-mediated
tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys. 1992, 298, 431–437. [CrossRef]
10. Teixeira, D.; Fernandes, R.; Prudêncio, C.; Vieira, M. 3-Nitrotyrosine quantification methods: Current
concepts and future challenges. Biochimie 2016, 125, 1–11. [CrossRef]
11. Nakabeppu, Y.; Ohta, E.; Abolhassani, N. MTH1 as a nucleotide pool sanitizing enzyme: Friend or foe?
Free Radic. Biol. Med. 2017, 107, 151–158. [CrossRef]
12. Valavanidis, A.; Vlachogianni, T.; Fiotakis, C. 8-hydroxy-2′-deoxyguanosine (8-OHdG): A critical biomarker
of oxidative stress and carcinogenesis. J. Environ. Sci. Health C 2009, 27, 120–139. [CrossRef] [PubMed]
13. Kasai, H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2′-deoxyguanosine, as a marker of
cellular oxidative stress during carcinogenesis. Mutat. Res. Rev. Mutat. Res. 1997, 387, 147–163. [CrossRef]
14. Reed, T.T. Lipid peroxidation and neurodegenerative disease. Free Radic. Biol. Med. 2011, 51, 1302–1319.
[CrossRef] [PubMed]
15. Cobley, J.N.; Fiorello, M.L.; Bailey, D.M. 13 Reasons why the brain is susceptible to oxidative stress. Redox Biol.
2018, 15, 490–503. [CrossRef]
16. Pacelli, C.; Giguère, N.; Bourque, M.-J.; Lévesque, M.; Slack, R.S.; Trudeau, L.-É. Elevated mitochondrial
bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons.
Curr. Biol. 2015, 25, 2349–2360. [CrossRef]
17. Tysnes, O.-B.; Storstein, A. Epidemiology of Parkinson’s disease. J. Neural Transm. 2017, 124, 901–905.
[CrossRef]
18. de Lau, L.M.; Breteler, M.M. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006, 5, 525–535. [CrossRef]
19. Miyazaki, I.; Asanuma, M. Dopaminergic Neuron-Specific Oxidative Stress Caused by Dopamine Itself.
Acta Med. Okayama 2008, 62, 10.
Methods Protoc. 2020, 3, 66 12 of 14
20. Anderson, J.P.; Walker, D.E.; Goldstein, J.M.; de Laat, R.; Banducci, K.; Caccavello, R.J.; Barbour, R.;
Huang, J.; Kling, K.; Lee, M.; et al. Phosphorylation of Ser-129 is the dominant pathological modification
of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006, 281, 29739–29752.
[CrossRef]
21. Wong, Y.C.; Krainc, D. α-Synuclein toxicity in neurodegeneration: Mechanism and therapeutic strategies.
Nat. Med. 2017, 23, 1–13. [CrossRef]
22. Hijaz, B.A.; Volpicelli-Daley, L.A. Initiation and propagation of α-synuclein aggregation in the nervous
system. Mol. Neurodegener. 2020, 15, 1–12. [CrossRef] [PubMed]
23. Braak, H.; Del Tredici, K.; Rüb, U.; de Vos, R.A.I.; Jansen Steur, E.N.H.; Braak, E. Staging of brain pathology
related to sporadic Parkinson’s disease. Neurobiol. Aging 2003, 24, 197–211. [CrossRef]
24. Selley, M.L. (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson’s disease. Free Radic.
Biol. Med. 1998, 25, 169–174. [CrossRef]
25. Rawlins, M.D.; Wexler, N.S.; Wexler, A.R.; Tabrizi, S.J.; Douglas, I.; Evans, S.J.W.; Smeeth, L. The Prevalence
of Huntington’s Disease. NED 2016, 46, 144–153. [CrossRef]
26. Bañez-Coronel, M.; Ayhan, F.; Tarabochia, A.D.; Zu, T.; Perez, B.A.; Tusi, S.K.; Pletnikova, O.; Borchelt, D.R.;
Ross, C.A.; Margolis, R.L.; et al. RAN translation in huntington disease. Neuron 2015, 88, 667–677. [CrossRef]
27. McColgan, P.; Tabrizi, S.J. Huntington’s disease: A clinical review. Eur. J. Neurol. 2018, 25, 24–34. [CrossRef]
28. Ross, C.A.; Tabrizi, S.J. Huntington’s disease: From molecular pathogenesis to clinical treatment. LancetNeurol.
2011, 10, 83–98. [CrossRef]
29. Kumar, A.; Ratan, R.R. Oxidative stress and Huntington’s disease: The good, the bad, and the ugly.
J. Huntington’s Dis. 2016, 5, 217–237. [CrossRef]
30. Moumné, L.; Betuing, S.; Caboche, J. Multiple aspects of gene dysregulation in Huntington’s disease.
Front. Neurol. 2013, 4, 127. [CrossRef]
31. Zheng, J.; Winderickx, J.; Franssens, V.; Liu, B. A mitochondria-associated oxidative stress perspective on
Huntington’s disease. Front. Mol. Neurosci. 2018, 11, 329. [CrossRef]
32. Duran, R.; Barrero, F.J.; Morales, B.; Luna, J.D.; Ramirez, M.; Vives, F. Oxidative stress and plasma
aminopeptidase activity in Huntington’s disease. J. Neural Transm. 2010, 117, 325–332. [CrossRef] [PubMed]
33. Browne, S.E.; Ferrante, R.J.; Beal, M.F. Oxidative stress in Huntington’s disease. Brain Pathol. 1999, 9, 147–163.
[CrossRef] [PubMed]
34. Polidori, M.C.; Mecocci, P.; Browne, S.E.; Senin, U.; Beal, M.F. Oxidative damage to mitochondrial DNA in
Huntington’s disease parietal cortex. Neurosci. Lett. 1999, 272, 53–56. [CrossRef]
35. Chen, C.-M.; Wu, Y.-R.; Cheng, M.-L.; Liu, J.-L.; Lee, Y.-M.; Lee, P.-W.; Soong, B.-W.; Chiu, D.T.-Y. Increased
oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington’s disease patients.
Biochem. Biophys. Res. Commun. 2007, 359, 335–340. [CrossRef] [PubMed]
36. Long, J.D.; Matson, W.R.; Juhl, A.R.; Leavitt, B.R.; Paulsen, J.S.; PREDICT-HD Investigators and Coordinators
of the Huntington Study Group. 8OHdG as a marker for Huntington disease progression. Neurobiol. Dis.
2012, 46, 625–634. [CrossRef]
37. Tramutola, A.; Lanzillotta, C.; Perluigi, M.; Butterfield, D.A. Oxidative stress, protein modification and
Alzheimer disease. Brain Res. Bull. 2017, 133, 88–96. [CrossRef]
38. Van Cauwenberghe, C.; Van Broeckhoven, C.; Sleegers, K. The genetic landscape of Alzheimer disease:
Clinical implications and perspectives. Genet. Med. 2016, 18, 421–430. [CrossRef]
39. Qiu, C.; De Ronchi, D.; Fratiglioni, L. The epidemiology of the dementias: An update. Curr. Opin. Psychiatry
2007, 20, 380–385. [CrossRef]
40. Prince, M.; Ali, G.-C.; Guerchet, M.; Prina, A.M.; Albanese, E.; Wu, Y.-T. Recent global trends in the prevalence
and incidence of dementia, and survival with dementia. Alzheimer’s Res. Ther. 2016, 8, 23. [CrossRef]
41. Lanoiselée, H.-M.; Nicolas, G.; Wallon, D.; Rovelet-Lecrux, A.; Lacour, M.; Rousseau, S.; Richard, A.-C.;
Pasquier, F.; Rollin-Sillaire, A.; Martinaud, O.; et al. APP, PSEN1, and PSEN2 mutations in early-onset
Alzheimer disease: A genetic screening study of familial and sporadic cases. PLoS Med. 2017, 14, e1002270.
[CrossRef]
42. Long, J.M.; Holtzman, D.M. Alzheimer disease: An update on pathobiology and treatment strategies. Cell
2019, 179, 312–339. [CrossRef] [PubMed]
43. Scheltens, P.; Blennow, K.; Breteler, M.M.B.; de Strooper, B.; Frisoni, G.B.; Salloway, S.; Van Der Flier, W.M.
Alzheimer’s disease. Lancet 2016, 388, 505–517. [CrossRef]
Methods Protoc. 2020, 3, 66 13 of 14
44. Yamazaki, Y.; Zhao, N.; Caulfield, T.R.; Liu, C.-C.; Bu, G. Apolipoprotein E and alzheimer disease:
Pathobiology and targeting strategies. Nat. Rev. Neurol. 2019, 15, 501–518. [CrossRef] [PubMed]
45. Serrano-Pozo, A.; Frosch, M.P.; Masliah, E.; Hyman, B.T. Neuropathological alterations in alzheimer disease.
Cold Spring Harb. Perspect. Med. 2011, 1, a006189. [CrossRef] [PubMed]
46. Tönnies, E.; Trushina, E. Oxidative stress, synaptic dysfunction, and alzheimer’s disease. J. Alzheimers Dis.
2017, 57, 1105–1121. [CrossRef]
47. Gibson, G.E.; Karuppagounder, S.S.; Shi, Q. Oxidant-induced changes in mitochondria and calcium dynamics
in the pathophysiology of Alzheimer’s disease. Ann. N. Y. Acad. Sci. 2008, 1147, 221–232. [CrossRef]
48. Manczak, M.; Anekonda, T.S.; Henson, E.; Park, B.S.; Quinn, J.; Reddy, P.H. Mitochondria are a direct site of
A beta accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative
damage in disease progression. Hum. Mol. Genet. 2006, 15, 1437–1449. [CrossRef]
49. Colell, A.; Fernández, A.; Fernández-Checa, J.C. Mitochondria, cholesterol and amyloid beta peptide:
A dangerous trio in Alzheimer disease. J. Bioenerg. Biomembr. 2009, 41, 417–423. [CrossRef]
50. Schippling, S.; Kontush, A.; Arlt, S.; Buhmann, C.; Stürenburg, H.J.; Mann, U.; Müller-Thomsen, T.;
Beisiegel, U. Increased lipoprotein oxidation in Alzheimer’s disease. Free Radic. Biol. Med. 2000, 28, 351–360.
[CrossRef]
51. Kim, T.-S.; Pae, C.-U.; Yoon, S.-J.; Jang, W.-Y.; Lee, N.J.; Kim, J.-J.; Lee, S.-J.; Lee, C.; Paik, I.-H.; Lee, C.-U.
Decreased plasma antioxidants in patients with Alzheimer’s disease. Int. J. Geriatr. Psychiatry 2006, 21,
344–348. [CrossRef]
52. Mecocci, P.; Beal, M.F.; Cecchetti, R.; Polidori, M.C.; Cherubini, A.; Chionne, F.; Avellini, L.; Romano, G.;
Senin, U. Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD
human brain. Mol. Chem. Neuropathol. 1997, 31, 53–64. [CrossRef] [PubMed]
53. Lovell, M.A.; Markesbery, W.R. Oxidative DNA damage in mild cognitive impairment and late-stage
Alzheimer’s disease. Nucleic Acids Res. 2007, 35, 7497–7504. [CrossRef] [PubMed]
54. Bradley-Whitman, M.A.; Timmons, M.D.; Beckett, T.L.; Murphy, M.P.; Lynn, B.C.; Lovell, M.A. Nucleic acid
oxidation: An early feature of Alzheimer’s disease. J. Neurochem. 2014, 128, 294–304. [CrossRef] [PubMed]
55. Reddy, P.H.; Beal, M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for
cognitive decline in aging and Alzheimer’s disease. Trends Mol. Med. 2008, 14, 45–53. [CrossRef]
56. Ellis, B.; Hye, A.; Snowden, S.G. Metabolic modifications in human biofluids suggest the involvement of
sphingolipid, antioxidant, and glutamate metabolism in Alzheimer’s disease pathogenesis. J. Alzheimers Dis.
2015, 46, 313–327. [CrossRef]
57. Butterfield, D.A.; Halliwell, B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease.
Nat. Rev. Neurosci. 2019, 20, 148–160. [CrossRef]
58. Prasad, K.N. Simultaneous activation of Nrf2 and elevation of antioxidant compounds for reducing oxidative
stress and chronic inflammation in human Alzheimer’s disease. Mech. Ageing Dev. 2016, 153, 41–47.
[CrossRef]
59. Longinetti, E.; Fang, F. Epidemiology of amyotrophic lateral sclerosis: An update of recent literature.
Curr. Opin. Neurol. 2019, 32, 771–776. [CrossRef]
60. Mehta, P. Prevalence of amyotrophic lateral sclerosis—United States, 2014. Morb. Mortal. Wkly. Rep. 2018, 67,
216–218. [CrossRef]
61. Banci, L.; Bertini, I.; Boca, M.; Girotto, S.; Martinelli, M.; Valentine, J.S.; Vieru, M. SOD1 and amyotrophic
lateral sclerosis: Mutations and oligomerization. PLoS ONE 2008, 3, 0001677. [CrossRef]
62. Rosen, D.R.; Siddique, T.; Patterson, D.; Figlewicz, D.A.; Sapp, P.; Hentati, A.; Donaldson, D.; Goto, J.;
O’Regan, J.P.; Deng, H.X. Mutations in Cu/Zn superoxide dismutase gene are associated with familial
amyotrophic lateral sclerosis. Nature 1993, 362, 59–62. [CrossRef]
63. Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature
2006, 443, 787–795. [CrossRef] [PubMed]
64. Niedzielska, E.; Smaga, I.; Gawlik, M.; Moniczewski, A.; Stankowicz, P.; Pera, J.; Filip, M. Oxidative stress in
neurodegenerative diseases. Mol. Neurobiol. 2016, 53, 4094–4125. [CrossRef] [PubMed]
65. Burbulla, L.F.; Song, P.; Mazzulli, J.R.; Zampese, E.; Wong, Y.C.; Jeon, S.; Santos, D.P.; Blanz, J.; Obermaier, C.D.;
Strojny, C.; et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s
disease. Science 2017, 357, 1255–1261. [CrossRef] [PubMed]
Methods Protoc. 2020, 3, 66 14 of 14
66. Konovalova, J.; Gerasymchuk, D.; Parkkinen, I.; Chmielarz, P.; Domanskyi, A. Interplay between MicroRNAs
and oxidative stress in neurodegenerative diseases. Int. J. Mol. Sci. 2019, 20, 6055. [CrossRef] [PubMed]
67. Surgucheva, I.; He, S.; Rich, M.C.; Sharma, R.; Ninkina, N.N.; Stahel, P.F.; Surguchov, A. Role of synucleins in
traumatic brain injury—An experimental in vitro and in vivo study in mice. Mol. Cell. Neurosci. 2014, 63,
114–123. [CrossRef]
68. Kim, G.H.; Kim, J.E.; Rhie, S.J.; Yoon, S. The role of oxidative stress in neurodegenerative diseases.
Exp. Neurobiol. 2015, 24, 325–340. [CrossRef]
69. Murphy, M.P. Antioxidants as therapies: Can we improve on nature? Free Radic. Biol. Med. 2014, 66, 20–23.
[CrossRef]
70. Katerji, M.; Filippova, M.; Duerksen-Hughes, P. Approaches and methods to measure oxidative stress in
clinical samples: Research applications in the cancer field. Oxidative Med. Cell. Longev. 2019, 2019, 1279250.
[CrossRef] [PubMed]
71. Tanapat, P. Neuronal cell markers. Mater. Methods 2020, 3, 196. [CrossRef]
72. Radulescu, R.T.; Boenisch, T. Blocking endogenous peroxidases: A cautionary note for immunohistochemistry.
J. Cell. Mol. Med. 2007, 11, 1419.
73. van der Loos, C.M. Multiple immunoenzyme staining: Methods and visualizations for the observation with
spectral imaging. J. Histochem. Cytochem. 2008, 56, 313–328. [CrossRef]
74. Oakes, K.D.; Van Der Kraak, G.J. Utility of the TBARS assay in detecting oxidative stress in white sucker
(Catostomus commersoni) populations exposed to pulp mill effluent. Aquat. Toxicol. 2003, 63, 447–463.
[CrossRef]
75. Devasagayam, T.P.A.; Boloor, K.K.; Ramasarma, T. Methods for estimating lipid peroxidation: An analysis of
merits and demerits. Indian J. Biochem. Biophys. 2003, 40, 300–308.
76. Sidorova, Y.A.; Perepechaeva, M.L.; Pivovarova, E.N.; Markel, A.L.; Lyakhovich, V.V.; Grishanova, A.Y.
Menadione suppresses benzo(α)pyrene-induced activation of cytochromes P450 1A: Insights into a possible
molecular mechanism. PLoS ONE 2016, 11, e0155135. [CrossRef]
77. Kolosova, N.G.; Grishanova, A.I.; Krysanova, Z.S.; Zueva, T.V.; Sidorova, I.A.; Sinitsyna, O.I. Age-related
changes in protein and lipid oxidation in the liver of prematurely aging rats OXYS. Biomeditsinskaya Khimiya
2004, 50, 73–78.
78. Penttinen, A.-M.; Parkkinen, I.; Blom, S.; Kopra, J.; Andressoo, J.-O.; Pitkänen, K.; Voutilainen, M.H.;
Saarma, M.; Airavaara, M. Implementation of deep neural networks to count dopamine neurons in substantia
nigra. Eur. J. Neurosci. 2018, 48, 2354–2361. [CrossRef]
79. Rieker, C.; Engblom, D.; Kreiner, G.; Domanskyi, A.; Schober, A.; Stotz, S.; Neumann, M.; Yuan, X.; Grummt, I.;
Schütz, G.; et al. Nucleolar disruption in dopaminergic neurons leads to oxidative damage and parkinsonism
through repression of mammalian target of rapamycin signaling. J. Neurosci. 2011, 31, 453–460. [CrossRef]
[PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
